Intocell Inc
287840
Company Profile
Business description
Intocell Inc possesses independent linker platform technology in the ADC (Antibody-Drug Conjugate) field, which is in the spotlight in the anticancer drug market. The company is researching linker technology that conjugates with drugs and drugs for ADC. The business model of the company is to continuously secure sales through platform technology export that allows linker platform technology to be applied to partner companies' antibodies, and technology export of ADC pipelines.
Contact
101 Sinildong-ro
Daedeok-gu
Daejeon
KORT: +82 427160083
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
46
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
Concerns about equity sales to finance AI investments have pressured shares.
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
AI data center revenue is growing fast, but questions about durability remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,200.77 | 274.33 | -0.52% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,135.07 | 414.79 | -1.56% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,710.17 | 18.84 | 0.14% |
| S&P 500 | 7,701.70 | 42.28 | -0.55% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |